Ballantyne, Christie M.
Neutel, Joel
Cropp, Anne https://orcid.org/0000-0002-1703-8043
Duggan, William
Wang, Ellen Q.
Plowchalk, David
Sweeney, Kevin
Kaila, Nitin
Vincent, John
Bays, Harold
Clinical trials referenced in this document:
Documents that mention this clinical trial
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
https://doi.org/10.1016/j.amjcard.2015.02.006
Documents that mention this clinical trial
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
https://doi.org/10.1016/j.amjcard.2015.02.006
Nonstatin Therapies for Management of Dyslipidemia: A Review
https://doi.org/10.1016/j.clinthera.2015.09.001
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
https://doi.org/10.1016/j.ahj.2016.05.010
LDL cholesterol: controversies and future therapeutic directions
https://doi.org/10.1016/s0140-6736(14)61009-6
Documents that mention this clinical trial
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
https://doi.org/10.1016/j.amjcard.2015.02.006
Nonstatin Therapies for Management of Dyslipidemia: A Review
https://doi.org/10.1016/j.clinthera.2015.09.001
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
https://doi.org/10.1016/j.ahj.2016.05.010
Funding for this research was provided by:
Pfizer
This article is maintained by: Elsevier
Article Title: Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
Journal Title: The American Journal of Cardiology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.amjcard.2015.02.006
Content Type: article
Copyright: Copyright © 2015 The Authors. Published by Elsevier Inc.